AngioDynamics (ANGO) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | $20.00 from $16.00 | Jul 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 from $16.00 | Jul 15, 2026 |
| Canaccord Genuity | Maintained | Buy | $16.00 from $18.00 | Apr 6, 2026 |
| Freedom Broker | Initiated Coverage | Buy | $16.00 | Apr 6, 2026 |
| Canaccord Genuity | Maintained | Buy | $18.00 from $17.00 | Oct 3, 2025 |
| Canaccord Genuity | Maintained | Buy | $17.00 from $15.00 | Jul 16, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Jul 16, 2025 |
| Lake Street | Initiated Coverage | Buy | $24.00 | Jul 16, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 from $15.00 | Apr 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $14.00 | Jan 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Dec 10, 2024 |
| Canaccord Genuity | Maintained | Buy | $12.00 from $13.00 | Oct 4, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Oct 4, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Sep 20, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Jul 17, 2024 |
| Canaccord Genuity | Maintained | Buy | $13.00 from $18.00 | Jul 17, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | May 22, 2024 |
| Oppenheimer | Upgraded | Perform → Outperform | $12.00 | Apr 5, 2024 |
| Raymond James | Maintained | Outperform | $10.00 from $12.00 | Jan 9, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $20.00 | Jan 8, 2024 |
Frequently asked questions
Is ANGO a buy, sell, or hold?
Analysts covering AngioDynamics currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ANGO?
On Jul 15, 2026, Canaccord Genuity maintained AngioDynamics at Buy with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.